- Home
- FSEA vs RNXT Comparison
FSEA vs RNXT Comparison
Compare FSEA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- RNXT
- Stock Information
- Founded
- FSEA 1890
- RNXT 2012
- Country
- FSEA United States
- RNXT United States
- Employees
- FSEA N/A
- RNXT N/A
- Industry
- FSEA Savings Institutions
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- FSEA Finance
- RNXT Health Care
- Exchange
- FSEA Nasdaq
- RNXT Nasdaq
- Market Cap
- FSEA 53.7M
- RNXT 44.6M
- IPO Year
- FSEA N/A
- RNXT 2021
- Fundamental
- Price
- FSEA $11.21
- RNXT $0.96
- Analyst Decision
- FSEA
- RNXT Strong Buy
- Analyst Count
- FSEA 0
- RNXT 2
- Target Price
- FSEA N/A
- RNXT $7.25
- AVG Volume (30 Days)
- FSEA 4.5K
- RNXT 193.1K
- Earning Date
- FSEA 08-08-2025
- RNXT 08-14-2025
- Dividend Yield
- FSEA N/A
- RNXT N/A
- EPS Growth
- FSEA N/A
- RNXT N/A
- EPS
- FSEA N/A
- RNXT N/A
- Revenue
- FSEA $14,095,000.00
- RNXT $662,000.00
- Revenue This Year
- FSEA N/A
- RNXT $3,104.65
- Revenue Next Year
- FSEA N/A
- RNXT $301.89
- P/E Ratio
- FSEA N/A
- RNXT N/A
- Revenue Growth
- FSEA 30.26
- RNXT N/A
- 52 Week Low
- FSEA $8.90
- RNXT $0.75
- 52 Week High
- FSEA $11.80
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- FSEA 43.66
- RNXT 30.04
- Support Level
- FSEA $10.13
- RNXT $1.23
- Resistance Level
- FSEA $11.48
- RNXT $1.37
- Average True Range (ATR)
- FSEA 0.18
- RNXT 0.09
- MACD
- FSEA -0.03
- RNXT -0.01
- Stochastic Oscillator
- FSEA 69.53
- RNXT 11.77
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.